Literature DB >> 26674732

Elevation of serum interleukins 8, 4, and 1β levels in patients with gastrointestinal low-grade B-cell lymphoma.

Tomoko Miyata-Takata1, Katsuyoshi Takata1, Tomohiro Toji1,2, Naoe Goto3, Senji Kasahara4, Takeshi Takahashi4, Akira Tari5, Mai Noujima-Harada1, Takafumi Miyata6, Yasuharu Sato1, Tadashi Yoshino1.   

Abstract

Proinflammatory cytokines that are produced by helper T cells (Th) regulate immune reactions, facilitate class switching of B cells, and prolong the lifespan of B and T cells. Eradication therapy using antibiotics is sometimes effective against gastrointestinal (GI) malignant lymphoma, suggesting that the tumor development or progression is affected by the inflammatory microenvironment. In the present study, serum samples from 148 patients with various subtypes of malignant lymphoma were tested for 11 proinflammatory Th1/Th2 cytokines. In the comparison by subtype or GI lesions, serum interleukin (IL)-8 (P = 6.7E-05), IL-4 (P = 7.5E-05), and IL-1β (P = 0.0043) levels showed significant differences among subtypes, being particularly elevated in follicular lymphomas (FL) and mucosa-associated lymphoid tissue (MALT) lymphomas. Serum IL-8 levels were elevated in GI-FL and MALT lymphomas, and serum IL-4 and IL-1 β levels were elevated in MALT lymphomas. These findings show that GI low-grade B-cell lymphoma could develop against the background of an inflammatory microenvironment. Thus, these cytokines may be useful as diagnostic markers and could provide new insights into tumor development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26674732      PMCID: PMC4682061          DOI: 10.1038/srep18434

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Eradication therapy using antibiotics is often effective against gastrointestinal (GI) mucosa–associated lymphoid tissue (MALT) lymphoma. More than 90% of gastric MALT lymphoma cases are associated with Helicobacter pylori (HP) infection, and 75% of them regress after HP eradication1. In addition to MALT lymphoma, some cases of rectal MALT lymphoma and gastric diffuse large B-cell lymphoma (DLBCL) show regression as a result of HP eradication therapy2345, suggesting that development or progression of GI lymphoma is affected by the host inflammatory microenvironment or immune reactions. MALT lymphoma is the most frequent subtype in the stomach, whereas follicular lymphoma (FL) is most common in the duodenum67. Studies have shown that in contrast to the nodal subtype, intestinal FL shares characteristics with MALT lymphoma such as clinicopathological features, immunoglobulin repertoire, and gene expression7. This observation suggests that an immune reaction to some stimuli may have role in the tumor development or progression of intestinal FL. Proinflammatory cytokines produced by helper T cells (Th) regulate immune reactions, and it is known that they facilitate class switching of B cells and prolong the lifespan of B and T cells8. Among patients with HP-related gastritis, several Th1/Th2 cytokines elevations were reported9. As for malignant lymphoma, relationship with Th1/Th2 cytokine profile is not well elucidated. In the present study, we tested the hypothesis that the profiles of serum Th1/Th2 cytokines of various lymphoma subtypes differ according to subtypes. We then focused on GI low-grade B-cell lymphoma, particularly FL and MALT lymphoma.

Results

Serum interleukin (IL)-8, IL-4 and IL-1β levels were different depending on a lymphoma subtype

Among the 11 analyzed cytokines, IL-8, IL-4, and IL-1β levels were significantly different from control depending on the lymphoma subtype using one-way analysis of variance among control and lymphoma subtypes (P = 6.69E−05, 7.46E−05, and 0.0043, respectively; Table 1). These three cytokines were also significantly different among the lymphoma subtypes (P = 1.63E−04, 1.15E−04, and 0.0040, respectively; Table 1). When we limited the analysis to three major subtypes (DLBCL, FL, and MALT lymphoma) and subdivided the cases by the presence or absence of GI lesions, these three cytokines also showed serum levels significantly different from controls using one-way analysis of variance among control and lymphoma subtypes (P = 0.0039, 0.00019, and 0.024, respectively; Table 2). These three cytokines were also significantly different among the lymphoma subtypes (P = 0.021, 0.00076, and 0.045, respectively; Table 2).
Table 1

Cytokine values according to each histological subtype.

 Subtype (n)DLBCL (55)FL (36)MALT(15)Others (42)(pg/ml)P*P**
Normal (21)
IL8Median180.193462.4041340.327159.92788.7316.69E-051.63E-04
SD341.955667.0292634.167287.289188.895
IL4Median18.9196.189137.72626.98310.5657.46E-051.15E-04
SD56.70732.751238.44769.0443.259
IL1βMedian2.90613.85679.4617.4086.0610.00430.0040
SD17.61749.704211.44524.65327.775
IL12p70Median26.780.75311.067120.25626.9150.650.54
SD185.6714.5231.793715.00987.175
IFNγMedian22.30507.679217.56700.0760.07
SD99.65024.516787.4690
IL2Median30.46329.9854.78928.70529.60.970.92
SD168.09664.583142.198117.611135.642
IL10Median814.1641.69613.149105.8942.1610.310.28
SD3733.8644.76523.435401.7169.905
IL6Median31.5097.83421.83117.6321.1690.730.77
SD155.88329.16275.66468.2595.357
IL5Median16.5091.85611.15313.9551.0210.820.81
SD104.19510.18543.19757.8414.679
TNFαMedian2.11719.33632.28519.2693.1040.140.15
SD11.30978.94571.47850.04914.226
TNFβMedian02.87505.41914.5090.390.54
SD017.252032.03466.487

DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue lymphoma

*P values were calculated among lymphoma subtypes and normal controls.

**P values were calculated among lymphoma subtypes.

Table 2

Cytokine values of each lymphoma subtype according to presence or absence of gastrointestinal lesion.

SubtypeDLBCL
FL
MALT
(pg/ml)P*P**
GI lesion (n)Present (8)Absent (23)Present (18)Absent (17)Present (11)Absent (4)Normal (21)
IL8Median48.626304.683777.218150.8611662.842453.4188.7310.00390.021
SD62.874469.097797.085273.9183044.377238.565188.895
IL4Median09.6382.87110.194170.97946.2810.5650.000190.00076
SD032.31512.17942.031269.292.5643.259
IL1βMedian01.422029.342108.35506.0610.0240.045
SD06.821070.153243.205027.775
IL12p70Median5.56559.8741.507015.092026.9150.860.823
SD15.74287.1456.392036.72087.175
IFNγMedian043.7670010.471000.410.502
SD0150.9350028.44800
IL2Median064.99239.63522.08874.713029.60.890.841
SD0258.52473.3757.087163.3120135.642
IL10Median236.9651453.790.1493.43315.1767.5732.1610.560.619
SD529.5035665.3830.6346.5726.13615.1459.905
IL6Median021.6236.07810.15529.1761.6331.1690.530.699
SD059.49.90341.75188.2583.2655.357
IL5Median0.25439.0623.3890.34315.20901.0210.680.735
SD0.718160.4114.3781.41450.44304.679
TNFαMedian00.77625.78413.64738.19216.043.1040.490.583
SD03.722109.39228.53581.85332.0814.226
TNFβMedian005.75100014.5090.770.635
SD0024.39800066.487

DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue lymphoma, GI: gastrointestinal

*P values were calculated among lymphoma subtypes and normal controls.

**P values were calculated among lymphoma subtypes.

Serum IL-8 level was elevated in GI low-grade B-cell lymphoma

The serum IL-8 level was elevated in FL and MALT lymphomas with GI lesions (P = 0.0039; Fig. 1A,B), and there was no difference between these two subtypes with GI lesions (P = 0.25; Fig. 1A). In FL, the serum IL-8 level in cases with GI lesions was higher than that in cases without GI lesions, but in MALT lymphomas, there was no difference between cases with and without GI lesions (Fig. 1A). Although the IL-8 value was higher in GI(−)DLBCL than in GI(+)DLBCL, it was not significantly different (P = 0.138).
Figure 1

Serum IL-8 level according to lymphoma subtype and with/without GI lesions.

(A) Serum IL-8 level was elevated in GI FL and MALT lymphomas. The IL-8 level was elevated in FL with GI lesions, but not in MALT lymphomas. (B) Among cases with GI lesions, serum IL-8 was elevated in FL and MALT lymphomas. There was no difference between FL and MALT lymphomas with GI lesions. IL: interleukin, GI: gastrointestinal, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue.

As for the 17 GI-FL, 16 nodal FL, and 10 GI-MALT lymphoma cases, interleukin-8 receptor β (IL-8RB) (CXCR2) protein expression was assessed using immunohistochemical analysis. Among the FL cases, IL-8RB expression was frequently observed in GI-FL cases (GI-FL: 17/17, nodal FL: 8/16; P = 0.0093; Fig. 2A,B), whereas all MALT lymphoma cases showed expression of IL-8RB (Fig. 2C). This result meant that the receptor of IL-8 was expressed in tumor tissue.
Figure 2

Immunohistochemical analysis of IL-8RB in representative FL and MALT lymphoma cases.

Intestinal FL (A) and gastric MALT lymphoma (C) tested positive for IL-8RB, but nodal FL tested negative (B). IL-8RB: interleukin-8 receptor β, GI: gastrointestinal, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue.

Serum IL-4 and IL-1β levels were elevated in GI-MALT lymphoma cases

Serum IL-4 and IL-1β levels were elevated in MALT lymphoma cases compared with healthy controls (P = 0.00019 and 0.024, respectively; Figs 3A and 4A). Both cytokines were also elevated when we analyzed only serum samples from MALT lymphoma cases with GI lesions (Figs 3B and 4B). In MALT lymphoma cases, the serum levels of both cytokines were not linked to the presence of GI lesions (P = 0.39 and 0.40, respectively; Figs 3A and 4A). Similarly, IL-4 and IL-1β were higher in GI−DLBCL than in GI+DLBCL, but they were not significantly different (P = 0.410, 0.045, respectively).
Figure 3

IL-4 serum levels by lymphoma subtypes and with/without GI lesions.

(A) Serum IL-4 levels were elevated in MALT lymphomas regardless of GI lesions. There were no differences between MALT lymphomas with and without GI lesions. (B) Among cases with GI lesions, serum IL-4 level was elevated in MALT lymphomas. IL: interleukin, GI: gastrointestinal, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue.

Figure 4

Serum IL-1β levels by lymphoma subtypes and with/without GI lesions.

(A) Serum IL-4 levels were elevated in MALT lymphomas regardless of GI lesions. There was no significant difference between MALT lymphomas with and without GI lesions. (B) Among cases with GI lesions, the serum IL-1β level was elevated in MALT lymphomas. IL: interleukin, GI: gastrointestinal, DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma, MALT: mucosa-associated lymphoid tissue.

Discussion

IL-8 (CXCL8) was first identified as a neutrophil chemoattractant that belongs to the CXC chemokine family10. IL-8 is a proinflammatory chemokine and an angiogenic factor that mediates various inflammatory responses and is associated with tumor progression11. In non–small cell lung carcinoma, IL-8 is overexpressed under the influence of KRAS and enhances the stromal response by inducing inflammation and angiogenesis, which are associated with tumor proliferation and negatively correlate with patients’ survival12. After antigen stimulation in the Peyer’s patch, B cells undergo class switching to IgA expressing α4β7 integrin and then home to the intestine via MAdCAM-1, which is expressed on endothelial cells of intestinal blood vessels13. Judging by the gene expression analysis reported previously, MAdCAM-1 and CCL20 were overexpressed in FL and MALT lymphoma tissue of the GI tract compared with the nodal counterpart14. This overexpression of MAdCAM-1 may be caused by the IL-8–induced angiogenesis. IL-4 is produced by Th2 cells, mast cells, and basophils and activates the JAK/STAT and PI3K pathways. In addition to the association of IL-4 with inflammatory responses and allergic reactions, B cells express IL-4 receptor, which promotes their proliferation as a co-mitogen, controls class switching to IgE or IgG4, and prolongs the cellular lifespan. IL-4 also makes B cells express THY1 by associating with lipopolysaccharides815. IL-1β is a component of the IL-1 complex and is linked to several inflammatory processes by activating macrophages. In addition to IL-8, we examined IL-4 receptor α (IL-4RA) immunostaining on 30 cases (10 GI FL, 10 nodal FL, and 10 GI MALT). In contrast to IL-8RB, IL-4RA was weakly positive for more than half of the cases regardless of the subtypes (P = 0.63) and was not reflected high serum IL-4 value in MALT lymphoma. (data not shown) It is suggested that IL-4 acts indirectly on tumor cells. Unfortunately an adequate level of IL-1 receptor antibody was not available. HP is known to be a major factor in the MALT lymphoma development. According to some researchers who performed cytokine expression analysis of HP-related and HP-unrelated gastritis, several Th1/Th2 cytokine combinations participate in the HP-related inflammation9. Elevation of IL-4, IL-8, IL-1β, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ levels was also observed. In HP-related gastritis caused by the CagA-positive strain, elevation of IL-1β and IL-18 levels was reported9. In the present study, elevation of IL-4, IL-1β, and IL-8 levels was detected in MALT lymphomas. This change may be caused by the HP-related inflammation. In another report, IL-4 production was found to be increased when a patient’s peripheral blood mononuclear cells (PBMCs) were stimulated by HP hsp60 or HP lysate16. Gene pleomorphism of the IL-4 gene and IL-1 receptor antagonist (IL-1RN) gene was reported to negatively correlate with HP-related gastric cancer17, suggesting that reactivity to such cytokines is linked to tumor development. In the present study, the correlation of HP infection with changes in cytokine production was not observed probably because of the insufficient sample size (Supplementary Figure). When confined to low-grade B-cell lymphoma, most of the cases were primary GI cases and a few cases were those of secondary GI involvement in this study. We could not examine if there were any clinicopathological differences between the primary and secondary cases because the number of secondary cases was a few. However, it is suggested that the cytokine profiles shown in this study reflected those of primary GI low-grade B-cell lymphoma. Although the main lesion of primary GI FL is often in the duodenum, total GI tract screening using double-balloon endoscopy revealed that 85% of the cases had lymphoma lesions that were broadly located in the GI tract7. In addition, some cases of MALT lymphoma of the stomach have concomitant lesions in the duodenum or colon. In our series, there was small number of patients whose GI lesion restricted to single organ were 6 cases (all stomach cases) for MALT, 13 (duodenum: 10, ileum: 3) for FL, 7 (stomach: 5, ileum: 1, colon: 1) for DLBCL. Considering these facts, HP +/− gastritis patients were not necessarily fit as adequate controls for this study as well as the inflammatory disease patients affecting corresponding organs, such as duodenitis, ileitis and colitis, because comparison among other subtypes, would be difficult. Therefore, we included healthy subjects as the controls in this study. It was reported that the clinical behavior of the GI FL cases was very indolent, similar to MALT lymphoma but in contrast to that of the nodal type718. Moreover GI FL was reported to have similar characteristics with MALT lymphoma, both in the immunohistochemical and molecular aspects including gene expression profiles1419. In the present study, GI FL and MALT lymphoma had similar elevations in serum IL-8; to discriminate MALT from GI FL, IL-4 and 1β elevations could be used. In this study, the functions of the cytokines indicated for the specific lymphoma subtypes were not investigated and warrant further study. For example, lymphoma development under the influence of specific cytokines using transgenic mice holding t(14;18) needs to be examined. To our knowledge, there is no report analyzing the proinflammatory cytokine profiles that are specific for GI lymphoma, and we believe that the relevance of this study is in the discovery of important serum cytokines, which could be the factors involved in the pathogenesis of lymphoma. In summary, analysis of Th1/Th2 cytokine levels in serum samples shows that IL-8 levels were elevated in GI FL and MALT lymphomas, whereas IL-4 and IL-1β levels were elevated in MALT lymphomas. These results show that GI low-grade B-cell lymphoma probably develops in an inflammatory microenvironment. This finding needs confirmation with a larger sample size, particularly for the utility of these cytokines as auxiliary diagnostic biomarkers. Further studies of the mechanisms involving these cytokines in the tumor microenvironment would be warranted and may lead to new therapeutic targets.

Methods

Clinical samples

Serum samples from 148 patients with malignant lymphoma were collected at our collaborating hospitals: Gifu University Hospital (June 2004–March 2012), Gifu City Hospital (March 2010–April 2015), and Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital (June 2011–May 2012). The samples from the patients included in this study are described in Table 3. The patient age had a median age of 62 years (range 41–83 years), and the male to female ratio was 16:15. Serum samples for all cases, except three, were taken before treatment. The three cases were as follows: 1 mantle cell lymphoma (MCL), 1 Hodgkin lymphoma (HL), and 1 MALT lymphoma (HP eradication therapy alone). The other clinical characteristics were obtained from 31 cases. The numbers of serum samples corresponding to each lymphoma subtype were as follows: 55 cases of DLBCLs including 2 intravascular large B-cell lymphomas (IVL), 36 FLs, 15 MALT lymphomas, and 42 other lymphomas (2 angioimmunoblastic T-cell lymphomas, 2 adult T-cell leukemias/ lymphomas, 2 acute lymphoblastic leukemias, 2 non-HLs, 2 Burkitt lymphomas, 1 hairy cell leukemia, 1 hepatosplenic T-cell lymphoma, 5 HLs, 3 MCLs, 4 natural killer (NK)/T-cell lymphomas, 15 peripheral T-cell lymphomas, 2 small lymphocytic lymphomas, and 1 cutaneous follicle center lymphoma). Serum samples from 21 healthy volunteers served as controls. Approval for the study protocol was obtained from the institutional review board at Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and similar boards at the collaborating hospitals. Informed consent was obtained from all subjects. All study procedures were conducted in accordance with the guidelines of the Declaration of Helsinki. In our hospital and other collaborating centers, diagnosis was based on the current WHO classification using appropriate immunostaining, such as CD20, 10, 5, BCL2, and cyclinD1 for low-grade B-cell lymphoma, and CD20, 10, and 5 for DLBCL6. In the analysis comparing the presence of GI lesions in DLBCL, FL, and MALT, cases of IVL (n = 2) and composite MALT and DLBCL (n = 1) were excluded. The behavior of composite MALT and DLBCL could not be investigated with a low sample number. Relevant information concerning involved sites was obtained from 81 out of 106 cases of major 3 subtypes (DLBCL, FL, and MALT). Among them, 37 had GI lesions and 28 of these were primary sites of lymphoma (case numbers of “primary GI cases” and “cases with secondary involvement or suspicious for secondary involvement of the GI tract” were 1 and 7 for DLBCL, 17 and 1 for FL, and 10 and 1 for MALT lymphoma, respectively).
Table 3

Cases included in this study.

HistologyTotalGastrointestinal lesion
PresentAbsent
DLBCL55823
FL361817
MALT15114
Others42  
Normal21  

DLBCL: diffuse large B-cell lymphoma, FL: follicular lymphoma,

MALT: mucosa-associated lymphoid tissue lymphoma.

Cytokine analysis

Eleven kinds of cytokines [IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, TNF-α, and TNF-β] were analyzed using the FlowCytomix Human Th1/Th2 11plex Kit BMS810FF (eBioscience, Vienna, Austria) and MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany).

Immunohistochemical analysis

Biopsy samples were fixed in 10% buffered formalin embedded in paraffin blocks and subjected to immunohistochemical analysis as described previously20. The clone of the antibody and dilution were 48311 and 1:100 for IL-8RB, and 25463 and 1:500 for IL-4RA, respectively (R&D Systems, Inc., Minneapolis, USA).

Statistical analysis

One-way analysis of variance was used. For statistical tests P < 0.05 was set as significant.

Additional Information

How to cite this article: Miyata-Takata, T. et al. Elevation of serum interleukins 8, 4, and 1β levels in patients with gastrointestinal low-grade B-cell lymphoma. Sci. Rep. 5, 18434; doi: 10.1038/srep18434 (2015).
  19 in total

1.  Regression of high-grade gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter pylori after triple antibiotic therapy.

Authors:  W W Ng; C P Lam; W K Chau; A Fen-Yau Li; C C Huang; F Y Chang; S D Lee
Journal:  Gastrointest Endosc       Date:  2000-01       Impact factor: 9.427

2.  Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

Authors:  C Berlin; E L Berg; M J Briskin; D P Andrew; P J Kilshaw; B Holzmann; I L Weissman; A Hamann; E C Butcher
Journal:  Cell       Date:  1993-07-16       Impact factor: 41.582

3.  Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines.

Authors:  T Yoshimura; K Matsushima; S Tanaka; E A Robinson; E Appella; J J Oppenheim; E J Leonard
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

Review 4.  The IL-4 receptor: signaling mechanisms and biologic functions.

Authors:  K Nelms; A D Keegan; J Zamorano; J J Ryan; W E Paul
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

5.  [Regression of primary rectal MALT lymphoma after Helicobacter pylori eradication].

Authors:  Kisato Nosaka; Takashi Shono; Yuji Yonemura; Ken-Ichi Iyama; Yutaka Sasaki; Shinya Endo; Yutaka Okuno; Hiroaki Mitsuya
Journal:  Rinsho Ketsueki       Date:  2014-08

6.  Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori.

Authors:  A C Wotherspoon; C Doglioni; T C Diss; L Pan; A Moschini; M de Boni; P G Isaacson
Journal:  Lancet       Date:  1993-09-04       Impact factor: 79.321

7.  Immune response in Helicobacter pylori-induced low-grade gastric-mucosa-associated lymphoid tissue (MALT) lymphoma.

Authors:  Rie Yamasaki; Kenji Yokota; Hiroyuki Okada; Shyunji Hayashi; Motowo Mizuno; Tadashi Yoshino; Yoshikazu Hirai; Daizou Saitou; Tadaatsu Akagi; Keiji Oguma
Journal:  J Med Microbiol       Date:  2004-01       Impact factor: 2.472

8.  Helicobacter pylori stimulates a mixed adaptive immune response with a strong T-regulatory component in human gastric mucosa.

Authors:  Rasmus Goll; Franz Gruber; Trine Olsen; Guanglin Cui; Gabriele Raschpichler; Magne Buset; Anne M Asfeldt; Anne Husebekk; Jon Florholmen
Journal:  Helicobacter       Date:  2007-06       Impact factor: 5.753

9.  Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: comprehensive analysis of 207 polymorphisms of 11 cytokine genes.

Authors:  Hiroshi Seno; Kiichi Satoh; Shingo Tsuji; Takayuki Shiratsuchi; Yosuke Harada; Nobuyuki Hamajima; Kentaro Sugano; Sunao Kawano; Tsutomu Chiba
Journal:  J Gastroenterol Hepatol       Date:  2007-05       Impact factor: 4.029

10.  Interleukin-4 and interleukin-13 signaling connections maps.

Authors:  Ann E Kelly-Welch; Erica M Hanson; Mark R Boothby; Achsah D Keegan
Journal:  Science       Date:  2003-06-06       Impact factor: 47.728

View more
  3 in total

Review 1.  The Role of Neutrophils in the Pathogenesis of Chronic Lymphocytic Leukemia.

Authors:  Malgorzata Wachowska; Alicja Wojciechowska; Angelika Muchowicz
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

2.  The Relationship Between Thrombo-Inflammatory Biomarkers and Cellular Indices of Inflammation in Lymphoma Patients.

Authors:  Mark Jaradeh; Nausheen Baig; Emily Bontekoe; Mirjana Mitrovic; Darko Antic; Debra Hoppensteadt; Bulent Kantarcioglu; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

3.  Tear cytokine profiles in patients with extranodal marginal zone B-cell lymphoma of the ocular adnexa.

Authors:  Wei Xiao; Jingqiao Chen; Huijing Ye; Xiaoyun Chen; Yuxiang Mao; Xian Ji; Shenglan Yang; Huasheng Yang
Journal:  Eye (Lond)       Date:  2021-06-28       Impact factor: 4.456

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.